AR002690A1 - DERIVATIVE OF BENCIMIDAZOLE OR SALTS OF THE SAME, PHARMACEUTICAL COMPOSITION, IMMUNOSUPPRESSIVE AGENT AND ANTI-INFLAMMATORY AGENT THAT CONTAIN IT AND PROCEDURES TO PREPARE SUCH DERIVATIVE. - Google Patents

DERIVATIVE OF BENCIMIDAZOLE OR SALTS OF THE SAME, PHARMACEUTICAL COMPOSITION, IMMUNOSUPPRESSIVE AGENT AND ANTI-INFLAMMATORY AGENT THAT CONTAIN IT AND PROCEDURES TO PREPARE SUCH DERIVATIVE.

Info

Publication number
AR002690A1
AR002690A1 ARP960103458A AR10345896A AR002690A1 AR 002690 A1 AR002690 A1 AR 002690A1 AR P960103458 A ARP960103458 A AR P960103458A AR 10345896 A AR10345896 A AR 10345896A AR 002690 A1 AR002690 A1 AR 002690A1
Authority
AR
Argentina
Prior art keywords
group
derivative
salts
bencimidazole
procedures
Prior art date
Application number
ARP960103458A
Other languages
Spanish (es)
Inventor
T Nishi
S Sato
T Nagatani
H Yukawa
N Koga
M Saito
S Yoshinaga
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR002690A1 publication Critical patent/AR002690A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Volume Flow (AREA)

Abstract

La presente invención provee derivados bencimidazol novedosos o sales de los mismos representados por la fórmula general (I), en donde R1 es un átomo dehidrógeno o un átomo de halógeno; R2 es un grupo alquilo inferior fenilo; R4 es un grupohet erocíclico seleccionado del grupo que consiste de un grupoindolilo, grupo indolinilo, grupo 1H-indazolilo, grupo 2(1H)-quinolinonilo, grupo 3,4-dihidro-2(1H)-quinolinonilo y grupo 1,4-benzoxazinilo; A es un grupoalquileno inferior; n es 0 ó1. Lo s derivados de bencimidazol o sus sales de la presente invención son agentes efectivos para tratar diversas enfermedadesarterioscleróticas.The present invention provides novel benzimidazole derivatives or salts thereof represented by the general formula (I), wherein R1 is a hydrogen atom or a halogen atom; R2 is a phenyl lower alkyl group; R4 is an erocyclic heth group selected from the group consisting of an indolyl group, indolinyl group, 1H-indazolyl group, 2 (1H) -quinolinonyl group, 3,4-dihydro-2 (1H) -quinolinonyl group, and 1,4-benzoxazinyl group ; A is a lower alkylene group; n is 0 or 1. The benzimidazole derivatives or their salts of the present invention are effective agents for treating various arteriosclerotic diseases.

ARP960103458A 1995-07-07 1996-07-05 DERIVATIVE OF BENCIMIDAZOLE OR SALTS OF THE SAME, PHARMACEUTICAL COMPOSITION, IMMUNOSUPPRESSIVE AGENT AND ANTI-INFLAMMATORY AGENT THAT CONTAIN IT AND PROCEDURES TO PREPARE SUCH DERIVATIVE. AR002690A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP17180795 1995-07-07

Publications (1)

Publication Number Publication Date
AR002690A1 true AR002690A1 (en) 1998-03-25

Family

ID=15930095

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960103458A AR002690A1 (en) 1995-07-07 1996-07-05 DERIVATIVE OF BENCIMIDAZOLE OR SALTS OF THE SAME, PHARMACEUTICAL COMPOSITION, IMMUNOSUPPRESSIVE AGENT AND ANTI-INFLAMMATORY AGENT THAT CONTAIN IT AND PROCEDURES TO PREPARE SUCH DERIVATIVE.

Country Status (16)

Country Link
US (1) US5998437A (en)
EP (1) EP0779887B1 (en)
KR (1) KR100231639B1 (en)
CN (1) CN1074413C (en)
AR (1) AR002690A1 (en)
AT (1) ATE201407T1 (en)
AU (1) AU703073B2 (en)
DE (1) DE69612949T2 (en)
DK (1) DK0779887T3 (en)
ES (1) ES2159036T3 (en)
GR (1) GR3036420T3 (en)
HK (1) HK1003436A1 (en)
MX (1) MX9701685A (en)
PT (1) PT779887E (en)
TW (1) TW381092B (en)
WO (1) WO1997003070A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
EP1120120A4 (en) * 1998-10-05 2009-04-29 Eisai R&D Man Co Ltd Tablets immediately disintegrating in the oral cavity
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
JP2003522760A (en) * 2000-02-09 2003-07-29 ザ プロクター アンド ギャンブル カンパニー 2-phenylcarbamoyl-benzimidazoles
EP1419770A4 (en) * 2001-08-24 2005-08-03 Shionogi & Co Apo ai expression accelerating agent
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7087790B2 (en) * 2003-08-29 2006-08-08 Rutgers, The State University Of New Jersey Benzotropolone derivatives and modulation of inflammatory response
AU2005324492B2 (en) 2004-04-23 2012-06-07 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US20090299067A1 (en) * 2008-05-30 2009-12-03 Pagoria Philip F New synthesis of 2,6-diamino-3,5-dinitropyrazine-1-oxide from 2,6-diaminopyrazine-1-oxide
WO2013159095A1 (en) * 2012-04-20 2013-10-24 Anderson Gaweco Ror modulators and their uses
JP6687550B2 (en) 2014-06-23 2020-04-22 セルジーン コーポレイション Apremilast for treating liver disease or liver dysfunction
ES2896400T3 (en) * 2014-08-01 2022-02-24 Nuevolution As Active compounds against bromdomains
KR102501049B1 (en) 2021-12-20 2023-02-20 김학용 Environment-affinitive panel for abalone cultivating shelter, environment-affinitive shelter assembly thereof, and abalone cultivation equipment using the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59148051A (en) * 1983-02-14 1984-08-24 Fuji Photo Film Co Ltd Photosensitive silver halide material
JPS61167952A (en) * 1985-01-21 1986-07-29 Fuji Photo Film Co Ltd Multi-layered silver halide color photosensitive material
JPH0749405B2 (en) * 1985-12-26 1995-05-31 三共株式会社 Renin-inhibiting peptide analogue
JPH0784462B2 (en) * 1986-07-25 1995-09-13 日清製粉株式会社 Benzimidazole derivative
US4851423A (en) * 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
JPH0820699B2 (en) * 1987-10-08 1996-03-04 富士写真フイルム株式会社 Direct positive color photographic light-sensitive material
US4994477A (en) * 1988-03-24 1991-02-19 Abbott Laboratories Heterocyclic renin inhibitors
JP2869561B2 (en) * 1989-05-22 1999-03-10 大塚製薬株式会社 Platelet adhesion inhibitor
KR920701167A (en) * 1989-07-07 1992-08-11 에릭 에스. 딕커 Pharmaceutically active compounds
US5098924A (en) * 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
MX9200299A (en) * 1991-02-07 1992-12-01 Roussel Uclaf NEW NITROGENATED BICYCLE DERIVATIVES, THEIR PROCEDURE FOR PREPARING THE NEW INTERMEDIATE COMPOUNDS OBTAINED THEIR APPLICATION AS MEDICINES AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
PT100905A (en) * 1991-09-30 1994-02-28 Eisai Co Ltd BICYCLE HYGIENEOUS HETEROCYCLIC COMPOUNDS CONTAINING BENZENE, CYCLOHEXAN OR PYRIDINE AND PYRIMIDINE, PYRIDINE OR IMIDAZOLE SUBSTITUTES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9121776D0 (en) * 1991-10-14 1991-11-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives and process for preparation thereof
PH31122A (en) * 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
JPH07133224A (en) * 1993-11-10 1995-05-23 Kyowa Hakko Kogyo Co Ltd Medicine for arteriosclerosis

Also Published As

Publication number Publication date
EP0779887A1 (en) 1997-06-25
ES2159036T3 (en) 2001-09-16
HK1003436A1 (en) 1998-10-30
ATE201407T1 (en) 2001-06-15
DK0779887T3 (en) 2001-11-26
DE69612949T2 (en) 2001-09-20
US5998437A (en) 1999-12-07
AU703073B2 (en) 1999-03-11
KR100231639B1 (en) 1999-11-15
KR970705559A (en) 1997-10-09
MX9701685A (en) 1997-06-28
PT779887E (en) 2001-08-30
TW381092B (en) 2000-02-01
CN1158129A (en) 1997-08-27
AU6318196A (en) 1997-02-10
WO1997003070A1 (en) 1997-01-30
GR3036420T3 (en) 2001-11-30
EP0779887B1 (en) 2001-05-23
CN1074413C (en) 2001-11-07
DE69612949D1 (en) 2001-06-28

Similar Documents

Publication Publication Date Title
AR002690A1 (en) DERIVATIVE OF BENCIMIDAZOLE OR SALTS OF THE SAME, PHARMACEUTICAL COMPOSITION, IMMUNOSUPPRESSIVE AGENT AND ANTI-INFLAMMATORY AGENT THAT CONTAIN IT AND PROCEDURES TO PREPARE SUCH DERIVATIVE.
ES2191048T3 (en) OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOUNDS THAT CONTAIN THEM.
ES2053508T3 (en) COMPOUNDS OF 3-PIRROLIDINYL-THIO-1-AZABICICLO (3.2.0) HEPT-2-ENO-2-CARBOXILICOS.
ES2142798T3 (en) DERIVATIVES OF 3-AMIDO PIRAZOL, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
ES2188194T3 (en) 1,8-NAFTIRIDIN-4 (1H) -ONON REPLACED AS INHIBITORS OF PHOSPHODESTERASE 4.
ATE242625T1 (en) CHELATE PREPARATIONS CONTAINING OXIME COMPOUNDS
NO971538L (en) Purine and guanine compounds as inhibitors of PNP
PE59399A1 (en) HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND METHODS TO INHIBIT THE RELEASE OF PEPTIDE � - AMYLOID AND / OR ITS SYNTHESIS THROUGH THE USE OF SUCH COMPOUNDS
TR200000671T2 (en) Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists.
PT89814A (en) METHOD FOR PREPARING NEW STYLBEN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ES2059335T3 (en) DERIVATIVES OF PIRIDO (3,2,1-IJ) -1,3,4-BENZOXADIAZINA, PROCEDURE FOR ITS OBTAINING, CORRESPONDING PHARMACEUTICAL PREPARATIONS AND INTERMEDIATE PRODUCTS USABLE IN THE PROCEDURE.
PE107999A1 (en) 3-AMIDINOANILINE DERIVATIVES, ACTIVATED BLOOD COAGULATION FACTOR X INHIBITORS AND INTERMEDIARIES THEREOF
TR200000670T2 (en) Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists.
KR890006590A (en) 4-aminopyridine derivative
CO5040004A1 (en) 2-4-DIAMINO-1,3,5-TRIAZINAS, ITS PREPARATION AND EMPLOYMENT AS HERBICIDES AND PHYTO-REGULATORS
FI803264L (en) 2-HYDROXIALKYL-3,4,5-TRIHYDROXIPIPERIDINER FOERFARANDE FOER FRAMSTAELLNING AV DEM OCH ANVAENDNING AV DEM SOM LAEKEMEDEL
ES2011427A4 (en) OXIN DERIVATIVES OF OCTAHIDRONAFTALENO FOR INHIBITION OF CHOLESTEROL SYNTHESIS, PROCESSES FOR ITS PREPARATION AND COMPOSITIONS THAT CONTAIN THEM.
IT1196423B (en) BENZOTIAZOLIN-COMPOUNDS
CO5580721A2 (en) FUNGICIDE COMPOSITION BASED ON AT LEAST A PYRIDYLMETILBENZAMIDE DERIVATIVE AND AT LEAST A DITIOCARBAMATE DERIVATIVE
AR021542A1 (en) A COMPOSITE OF SULFONAMIDE AND THE PHARMACEUTICAL COMPOSITIONS AND PREPARATIONS CONTAINING IT
SE9001269L (en) 2-SUBSTITUTED N, N'-DITRIMETOXBENZOYL PIPERAZINES, AND A PREPARATION METHOD FOR THESE AND THERAPEUTIC COMPOSITIONS CONTAINING THEM
DE69702775D1 (en) Quinolinone derivatives and antiallergic compositions containing them
ES2057415T3 (en) BICYCLE DERIVATIVES.
ES2045514T3 (en) USE OF CHROMAN DERIVATIVES FOR THE TREATMENT OF DEPRESSIVE STATES.
AR004680A1 (en) DERIVATIVES OF THE ALQUENIL-BENZOILGUANIDINA, PROCEDURE TO PREPARE THEM AND PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM.

Legal Events

Date Code Title Description
FB Suspension of granting procedure